MBOT vs SSYS

Analysts rate Microbot Medical Inc.

(MBOT) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Stratasys Ltd.

(SSYS) delivered a total return of -59. 1%, compared to -69. 7% for Microbot Medical Inc. (MBOT). Over 10 years, the gap is even starker: SSYS returned -60. 6% versus MBOT's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Stratasys Ltd.

(SSYS) is the lower-risk stock at 1. 79β versus Microbot Medical Inc. 's 1. 85β — meaning MBOT is approximately 4% more volatile than SSYS relative to the S&P 500. On balance sheet safety, Stratasys Ltd. (SSYS) carries a lower debt/equity ratio of 3% versus 3% for Microbot Medical Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Microbot Medical Inc.

grew EPS 30. 5% year-over-year, compared to 24. 7% for Stratasys Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Microbot Medical Inc.

(MBOT) is the more profitable company, earning 0. 0% net margin versus -18. 9% for Stratasys Ltd. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MBOT leads at 0. 0% versus -10. 7% for SSYS. At the gross margin level — before operating expenses — SSYS leads at 47. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for MBOT: 158.

2% to $5. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Stratasys Ltd.

(SSYS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Microbot Medical Inc. (MBOT) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SSYS: -60. 6%, MBOT: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MBOT (Healthcare) and SSYS (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.